Plasma metabolism markers related to intracranial aneurysm and application thereof

Abstract

The invention discloses a group of plasma metabolism markers related to intracranial aneurysm and application of the plasma metabolism markers. The markers comprise oxidized glutathione, reduced glutathione, methyl beta-D-galactopyranoside, koji disaccharide, D-pinose, dopaquinone, indoleacetaldehyde, 5, 5 '-dihydroxyacetophenone, beta-glucopyranosyl-beta-D-glucopyranosyl-beta-D-glucopyranosyl-beta-D-glucopyranosyl The reagent is prepared from 2, 6-dimethylbenzimidazole, N-palmitoyl glycine, uracil, indole-3-acetic acid and 1-acetyl indole. According to the invention, the plasma is used as a detection object, and the sample is noninvasive and easier to obtain, can be used for large-scale screening, is beneficial to early diagnosis and dynamic monitoring of intracranial aneurysm, and reduces huge risks brought to patients by rupture of intracranial aneurysm; small molecule metabolites are used as diagnostic markers, and the detection method is simple, can be used in the field of rapid diagnosis, and is good in detection specificity and high in accuracy; compared with protein and gene as disease diagnosis markers, the method has superiority.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a group of intracranial aneurysm-related plasma metabolic markers and applications thereof. Background technique [0002] Intracranial aneurysm (IA) is a cerebrovascular disease characterized by local tumor-like protrusions of intracranial arteries, and its etiology involves a variety of environmental and genetic factors. The prevalence of intracranial aneurysms in the Chinese population is about 5%. In cerebrovascular accidents, intracranial aneurysms rank third only after cerebral infarction and hypertensive cerebral hemorrhage. However, the risk of surgery, Postoperative morbidity and mortality rates are much higher than those of cerebral infarction and hypertensive cerebral hemorrhage, and are common cerebrovascular diseases that seriously threaten people's health. Before rupture and bleeding, 90% of patients with intracranial aneurysms have no obvious symptoms and signs, and on...

AI Technical Summary

Problems solved by technology

Biomarkers that use tissue as the detection sample type are invasive and cannot be used for early screening and diagnosis of intracranial aneurysms

Peripheral blood is used as the biomarker of the detection sample type, which needs to be completed through genomic DNA extraction-sequencing / chip detection, RNA extraction-reverse transcription-amplification, immune reaction, etc. The process is complex, time-consuming, and requires high storage of samples

Moreover, most of the above-mentioned detection methods use a single protein or a single gene as a detection marker. The specificity and accuracy of the method are low, and it cannot meet the higher clinical needs and large-scale accurate screening of the population.

Aiming at the existing methods of combined detection of serum markers and protein factors through mass spectrometry, chips, high-throughput sequencing platforms, kits, and test papers to diagnose intracranial aneurysms and predict the rupture potential of intracranial aneurysms, this method to a certain extent It solves the shortcomings of invasive inspection, but the detection method for macromolecules requires high storage conditions for samples and the process is complicated, time-consuming, and is easily interfered by high-abundance proteins in serum, which affects the specificity and accuracy of detection , so this kind of serum protein factor detection method also has certain limitations

Images